Jesse Boehm is the associate director of the Broad’s Cancer Program and a Merkin Institute Research Fellow. In these roles, he leads a research team while working closely with Cancer Program director Todd Golub in the scientific planning and strategic execution of program projects, collaborations, and activities.
The Boehm lab is focused on developing powerful methods and tools to accelerate the translation of cancer genomics into cancer therapeutics. Active projects include developing pipelines for personalized testing of tumor vulnerabilities as part of the Cancer Cell Line Factory, assessing the tumorigenic potential of thousands of new cancer mutations as part of the Target Accelerator, and developing systematic experimental and computational approaches to validate biomarker-dependency relationships as part of Project Achilles.
Previously, Boehm worked as a research scientist in the Broad Cancer Program. In this role he managed several large, collaborative research efforts that spanned multiple platforms, programs, and initiatives at the Broad Institute and Dana-Farber Cancer Institute. These included the generation of functional genomics tools for the community as well as the deployment of these tools in systematic, high-throughput experiments to determine the function of elements in the cancer genome.
Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the laboratory of William Hahn at the Dana-Farber Cancer Institute, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous.
Hong AL, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications. 2016. PMID: 27329820.
Kim E, et al. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. Cancer Discovery. [Published online ahead of print on May 4, 2016.] PMID: 27147599.
Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nature Reviews Genetics. 2015. PMID: 26077369
Lohr JG, et al. Whole-genome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology. [Published online ahead of print on April 20, 2014.] DOI:10.1038/nbt.2892